Drug Profile
Research programme: xerostomia therapy - Medpharma/Straumann
Alternative Names: Xerostomia research programme - Medpharma/StraumannLatest Information Update: 05 May 2008
Price :
$50
*
At a glance
- Originator Institut Straumann
- Class
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Xerostomia
Most Recent Events
- 05 May 2008 Discontinued - Phase-I for Xerostomia in Sweden (unspecified route)
- 24 Aug 2004 Biora has been acquired by, and merged into, Institut Straumann
- 19 Apr 2001 Phase-I clinical trials for Xerostomia in Sweden (Unknown route)